

David D Schlaepfer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9486462/publications.pdf>

Version: 2024-02-01

27
papers

5,953
citations

304743

22
h-index

526287

27
g-index

30
all docs

30
docs citations

30
times ranked

9701
citing authors

#	ARTICLE	IF	CITATIONS
1	Focal adhesion kinase: in command and control of cell motility. <i>Nature Reviews Molecular Cell Biology</i> , 2005, 6, 56-68.	37.0	2,193
2	FAK in cancer: mechanistic findings and clinical applications. <i>Nature Reviews Cancer</i> , 2014, 14, 598-610.	28.4	1,061
3	Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. <i>Nature Medicine</i> , 2016, 22, 497-505.	30.7	456
4	Nuclear FAK Promotes Cell Proliferation and Survival through FERM-Enhanced p53 Degradation. <i>Molecular Cell</i> , 2008, 29, 9-22.	9.7	421
5	VEGF-Induced Vascular Permeability Is Mediated by FAK. <i>Developmental Cell</i> , 2012, 22, 146-157.	7.0	281
6	Focal adhesion kinase signaling in unexpected places. <i>Current Opinion in Cell Biology</i> , 2017, 45, 24-30.	5.4	173
7	Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. <i>Journal of Cell Biology</i> , 2014, 204, 247-263.	5.2	163
8	Targeting FAK in anticancer combination therapies. <i>Nature Reviews Cancer</i> , 2021, 21, 313-324.	28.4	154
9	PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. <i>Cancer Biology and Therapy</i> , 2010, 9, 764-777.	3.4	144
10	Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 579-594.	3.3	97
11	Knock-in Mutation Reveals an Essential Role for Focal Adhesion Kinase Activity in Blood Vessel Morphogenesis and Cell Motility-Polarity but Not Cell Proliferation. <i>Journal of Biological Chemistry</i> , 2010, 285, 21526-21536.	3.4	95
12	FAK/PYK2 promotes the Wnt/ β -catenin pathway and intestinal tumorigenesis by phosphorylating GSK3 β . <i>ELife</i> , 2015, 4, .	6.0	93
13	Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. <i>Journal of Cell Biology</i> , 2012, 197, 907-919.	5.2	92
14	FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. <i>ELife</i> , 2019, 8, .	6.0	76
15	FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. <i>EMBO Molecular Medicine</i> , 2020, 12, e12010.	6.9	54
16	FAK Inhibition Disrupts a β 5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2050-2061.	4.1	52
17	Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 104-111.	1.4	47
18	Nuclear Focal Adhesion Kinase Controls Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia Through GATA4-Mediated Cyclin D1 Transcription. <i>Circulation Research</i> , 2019, 125, 152-166.	4.5	47

#	ARTICLE	IF	CITATIONS
19	Integrin adhesions. <i>Cell Adhesion and Migration</i> , 2012, 6, 302-306.	2.7	46
20	Oxidized LDL induces FAK-dependent RSK signaling to drive NF- κ B activation and VCAM-1 expression. <i>Journal of Cell Science</i> , 2016, 129, 1580-91.	2.0	45
21	FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth. <i>Breast Cancer Research</i> , 2015, 17, 47.	5.0	39
22	Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2117065119.	7.1	26
23	Rgnef promotes ovarian tumor progression and confers protection from oxidative stress. <i>Oncogene</i> , 2019, 38, 6323-6337.	5.9	25
24	Integrin α 4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN ^{low} Neuroblastoma. <i>PLoS ONE</i> , 2015, 10, e0120815.	2.5	21
25	A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer. <i>Oncotarget</i> , 2015, 6, 31104-31118.	1.8	18
26	Adaptive Resistance to Chemotherapy, A Multi-FAK-torial Linkage. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 719-723.	4.1	14
27	FAK Activation Promotes SMC Dedifferentiation via Increased DNA Methylation in Contractile Genes. <i>Circulation Research</i> , 2021, 129, e215-e233.	4.5	12